Su Zhigui, Xing Lei, Chen Yinan, Xu Yurui, Yang Feifei, Zhang Can, Ping Qineng, Xiao Yanyu
Department of Pharmaceutics, State Key Laboratory of Natural Medicines, China Pharmaceutical University , Nanjing 210009, P. R. China.
Mol Pharm. 2014 Jun 2;11(6):1823-34. doi: 10.1021/mp500238m. Epub 2014 May 15.
In this study, a dual-targeting drug delivery system based on bovine serum albumin nanoparticles (BSA-NPs) modified with both lactoferrin (Lf) and mPEG2000 loading doxorubicin (DOX) was designed, and its blood-brain barrier (BBB) penetration and brain glioma cells targeting properties were explored. BSA-NPs were prepared by a desolvation technique, and mPEG2000 was incorporated onto the surface of BSA-NPs by reacting with the free amino-group of BSA to form mPEG2000-modified BSA-NPs (P2000-NPs). Finally, Lf-modified P2000-NPs (Lf-NPs) was obtained by absorbing Lf onto the surface of P2000-NPs via the positive and negative charges interaction at physiological pH. Three levels of mPEG2000 and Lf-modified NPs were prepared and characterized, respectively. The uptake and potential cytotoxicity of different DOX preparations in vitro by the primary brain capillary endothelial cells (BCECs) and glioma cells (C6) were investigated. The dual-targeting effects were studied on the BBB model in vitro, BCECs/C6 glioma coculture model in vitro, and C6 glioma-bearing rats in vivo, respectively. The results exhibited that, with the increase of the amount of both mPEG2000 and Lf, the particle size of NPs increased and its zeta potential decreased. The in vivo pharmacokinetics study in healthy rats exhibited that P2000-NPs with a high level of mPEG2000 (P2000H-NPs) had longer circulation time in vivo. Compared to other NPs, Lf-NPs with high level of both Lf and mPEG2000 (LfH-NPs) showed the strongest cytotoxicity and the highest effectiveness in the uptake both in BCECs and C6 as well as improved the dual-targeting effects. Body distribution of DOX in different formulations revealed that LfH-NPs could significantly increase the accumulation of DOX in the brain, especially at 2 h postinjection (P < 0.05). In conclusion, Lf-NPs were a prospective dual-targeting drug delivery system for effective targeting therapy of brain gliomas.
在本研究中,设计了一种基于乳铁蛋白(Lf)和负载阿霉素(DOX)的甲氧基聚乙二醇2000(mPEG2000)修饰的牛血清白蛋白纳米粒(BSA-NPs)的双靶向给药系统,并探究了其血脑屏障(BBB)穿透能力和脑胶质瘤细胞靶向特性。通过去溶剂化技术制备BSA-NPs,使mPEG2000与BSA的游离氨基反应,将其引入BSA-NPs表面,形成mPEG2000修饰的BSA-NPs(P2000-NPs)。最后,在生理pH值下,通过正负电荷相互作用将Lf吸附到P2000-NPs表面,得到Lf修饰的P2000-NPs(Lf-NPs)。分别制备并表征了三个水平的mPEG2000和Lf修饰的纳米粒。研究了不同DOX制剂在体外对原代脑毛细血管内皮细胞(BCECs)和胶质瘤细胞(C6)的摄取及潜在细胞毒性。分别在体外BBB模型、BCECs/C6胶质瘤共培养模型以及体内C6荷瘤大鼠模型上研究了双靶向效果。结果表明,随着mPEG2000和Lf含量的增加,纳米粒粒径增大,zeta电位降低。健康大鼠体内药代动力学研究表明,mPEG2000含量高的P2000-NPs(P2000H-NPs)在体内循环时间更长。与其他纳米粒相比,Lf和mPEG2000含量均高的Lf-NPs(LfH-NPs)在BCECs和C6细胞中表现出最强的细胞毒性和最高的摄取效率,并且改善了双靶向效果。不同制剂中DOX的体内分布显示,LfH-NPs可显著增加DOX在脑内的蓄积,尤其是在注射后2小时(P<0.05)。综上所述,Lf-NPs是一种用于脑胶质瘤有效靶向治疗的有前景的双靶向给药系统。